Targeted Transformation of Diabetes Care in India
Bio Spectrum|BioSpectrum India Nov 2024
According to the International Diabetes Federation (IDF) about 63 per cent of people with diabetes say that the fear of developing diabetes-related complications affects their well-being. And around 28 per cent of people with diabetes find it hard to remain positive in relation to their condition. Hence the theme for this year's World Diabetes Day (WDD) 2024-26 observed on November 14, the world's largest diabetes awareness campaign reaching a global audience of over 1 billion people in over 160 countries, is Diabetes and well-being. Let's look at ways to reduce or reverse diabetes in India.
Vandana lyer
Targeted Transformation of Diabetes Care in India

The Indian Council of Medical Research– India Diabetes (ICMR-INDIAB) study published in 2023 reported that the overall weighted prevalence of diabetes in India was 11·4 per cent, accounting for 101 million people. The study findings also reported an alarming increase in non-communicable diseases (NCDs) such as prediabetes, hypertension, and obesity. Hence, there is a rising need to holistically manage the rising diabetes prevalence by improving awareness, diet, lifestyle, screening, treatment and monitoring practices in India.

Public and Private Campaigns for Improving Awareness

A study of the National Family Health Survey of India (NFHS), 2019–2021 reported that diabetes awareness varied from 14.4 per cent to 54.4 per cent. Not surprisingly, the less educated and poorer sections of the society had lower diabetes awareness. Thus, considering the rising prevalence of the disease, there is a need to improve diabetes awareness in India. Several public and private initiatives are looking to address this concern.

However, it is important to ensure that the awareness campaigns have wider outreach.

For instance, mDiabetes, launched in collaboration with the Ministry of Health and Family Welfare, India and the World Health Organization (WHO) aims to provide basic diabetes information to users who dial a missed call to a number. This is likely to ensure a wide outreach as even rural Indian sectors have good mobile connectivity in India. In 2021, the Research Society for the Study of Diabetes in India (RSSDI) launched the Defeat Diabetes Campaign to reach out to over 100 million people in 100 days to ‘test, track and treat’ diabetes. The campaign was successful and managed to screen over 106 million people in over 10,000 locations in India. There is a need to continue such targeted campaigns with well-defined outcomes and timelines.

Denne historien er fra BioSpectrum India Nov 2024-utgaven av Bio Spectrum.

Start din 7-dagers gratis prøveperiode på Magzter GOLD for å få tilgang til tusenvis av utvalgte premiumhistorier og 9000+ magasiner og aviser.

Denne historien er fra BioSpectrum India Nov 2024-utgaven av Bio Spectrum.

Start din 7-dagers gratis prøveperiode på Magzter GOLD for å få tilgang til tusenvis av utvalgte premiumhistorier og 9000+ magasiner og aviser.

FLERE HISTORIER FRA BIO SPECTRUMSe alt
Amit Agrawal steps in as new Pharmaceuticals Secretary
Bio Spectrum

Amit Agrawal steps in as new Pharmaceuticals Secretary

Amit Agrawal, the Chief Executive Officer (CEO) of the Unique Identification Authority of India (UIDAI), has been appointed as the new Secretary of the Department of Pharmaceuticals, Government of India.

time-read
1 min  |
BioSpectrum Indian Feb 2025
IIT-B joins hands with Tohoku University to offer MTech, PhD dual degree programmes
Bio Spectrum

IIT-B joins hands with Tohoku University to offer MTech, PhD dual degree programmes

The Indian Institute of Technology, Bombay (IIT-B) has entered into a Memorandum of Understanding (MoU) with Japan's Tohoku University to launch the IIT Bombay-Tohoku University Joint Academic & Research Programme.

time-read
1 min  |
BioSpectrum Indian Feb 2025
Innovative injectable hydrogel to offer targeted breast cancer therapy
Bio Spectrum

Innovative injectable hydrogel to offer targeted breast cancer therapy

In a multi-institutional research led by researchers from Indian Institute of Technology Guwahati (IIT-G) and Bose Institute Kolkata, an advanced injectable hydrogel has been developed for localised cancer treatment.

time-read
1 min  |
BioSpectrum Indian Feb 2025
Bio-Techne, Waters ink co-marketing agreement for biotherapeutic characterisation
Bio Spectrum

Bio-Techne, Waters ink co-marketing agreement for biotherapeutic characterisation

American life sciences company Bio-Techne Corporation, a leader in automated platforms for biotherapeutic characterisation, has announced a co-marketing and co-promotion agreement with Waters Corporation aimed at expanding the reach of advanced biotherapeutic characterisation and development processes.

time-read
1 min  |
BioSpectrum Indian Feb 2025
Nano-formulation of darkness hormone to serve as therapeutic solution for Parkinson's disease
Bio Spectrum

Nano-formulation of darkness hormone to serve as therapeutic solution for Parkinson's disease

Scientists from Institute of Nano Science and Technology (INST) Mohali have proved that nano-formulation of Melatonin, the hormone produced by the brain in response to darkness, showed improved antioxidative and neuroprotective properties and could be a potential therapeutic solution for Parkinson's disease (PD).

time-read
1 min  |
BioSpectrum Indian Feb 2025
"Govt should facilitate low-interest loans or VC funding specifically for biopharma startups & small enterprises"
Bio Spectrum

"Govt should facilitate low-interest loans or VC funding specifically for biopharma startups & small enterprises"

\"In a recent development, Nagpur-based biotech company GeNext Genomics (GNG) has joined -hands with Merck Life Science to support the Indian biotech system, particularly in the area of biomanufacturing, which is garnering more attention after the approval of the BioE3 policy.Supriya Kashikar, Founder & Chief Executive Officer, GeNext Genomics shares her views with BioSpectrum on the growth of biomanufacturing sector in India, and how the company plans to play a relevant role in this aspect.

time-read
4 mins  |
BioSpectrum Indian Feb 2025
Redcliffe Labs reinforces strategic leadership as Aditya Kandoi steps into CEO role, Dheeraj Jain as Chairman
Bio Spectrum

Redcliffe Labs reinforces strategic leadership as Aditya Kandoi steps into CEO role, Dheeraj Jain as Chairman

Redcliffe Labs, a purpose-driven pan-India omnichannel diagnostics service provider, has announced a strategic leadership transition.

time-read
1 min  |
BioSpectrum Indian Feb 2025
Zyla Health on-boards Rohit Boda as Advisor
Bio Spectrum

Zyla Health on-boards Rohit Boda as Advisor

Gurugram-based Zyla Health, a care management platform, has announced the onboarding of renowned industry leader, Rohit Boda, to the Board of Advisors.

time-read
1 min  |
BioSpectrum Indian Feb 2025
Claypond Capital appoints Shravan Subramanyam to lead medtech platform
Bio Spectrum

Claypond Capital appoints Shravan Subramanyam to lead medtech platform

Claypond Capital, the family investment office of Dr Ranjan Pai, has announced the appointment of Dr Shravan Subramanyam as the head of its medical technology platform.

time-read
1 min  |
BioSpectrum Indian Feb 2025
How AI Innovations at GCCs Solidifying India's Position in Global Life Sciences Industry
Bio Spectrum

How AI Innovations at GCCs Solidifying India's Position in Global Life Sciences Industry

India's life sciences sector is undergoing a major transformation, led by the expansion of Global Capability Centres GCCs). These centres, which serve as strategic hubs for multinational companies in pharmaceuticals, biotechnology, and healthcare, are strengthening India's role in the global life sciences landscape. Currently, there are over 95 life sciences GCCs in India, employing approximately 280,000 professionals. By 2030, this number is projected to reach 160 GCCs and around 420,000 employees. Advancements in artificial intelligence AI) are central to this transformation, driving innovation across drug discovery and clinical research. India's life sciences GCCs have evolved from operational support centres to world-class R&D engines, leveraging India’s robust talent pool, advanced technology adoption, and cost advantages. These GCCs are driving the future of Al-powered drug discovery and clinical research. Let’s explore further.

time-read
4 mins  |
BioSpectrum Indian Feb 2025